iCAD and Matakina to Integrate Breast Density Assessment with CAD for Mammography

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that it has entered into a distribution partnership with Mtakina (New Zealand), makers of Volpara� Volumetric Breast Density assessment software. With this agreement, iCAD will integrate Volpara software into its Computer-Aided Detection (CAD) systems, providing customers an objective breast density assessment tool with its CAD offerings.

"We look forward to this partnership with iCAD, a leader in the mammography market with a large installed base and strong distribution channels, to help bring our breast density solutions to a wider market."

Traditional breast density assessment tools have relied on visual assessment and have been subjective, varying widely among interpreting physicians and between sessions. Subjective measurement makes the analysis of breast changes over time much more difficult. Volpara provides an easy to implement, objective volumetric assessment of breast tissue density. Using digital images and information captured in every mammographic exam, the system applies a state-of-the-art algorithm that converts the qualitative breast x-ray image into quantitative data that can then be analyzed by the radiologist to estimate breast density.

aStudies have shown that women with denser breasts are at higher risk of breast cancer. We also know that the interpretation of breast density on a 2D mammography image can be challenging for the radiologist. The need for an objective measurement tool for breast density is clear,a said Ken Ferry, President and CEO of iCAD. aBy integrating Mtakinaa�s breast density assessment tool with iCADa�s CAD systems, we can offer radiologists a more comprehensive objective measurement tool for breast density, which will help in the assessment of mammograms.a

Recently, the state of Connecticut enacted legislation mandating that breast density be reported to patients along with their mammogram results. Legislators in other states including New York, California, Texas and Massachusetts also currently have efforts underway to require that women be informed of their breast density.

aBoth iCAD and Mtakina technologies aim to make the assessment of mammograms more precise and objective for the radiologist,a said Gerald Kolb, Vice President of Business Development for Mtakina International Ltd. aWe look forward to this partnership with iCAD, a leader in the mammography market with a large installed base and strong distribution channels, to help bring our breast density solutions to a wider market.a

iCADa�s SecondLook� Digital utilizes advanced pattern recognition technology and is extremely proficient in helping the radiologist detect cancers. Using a sophisticated algorithm, the CAD software identifies and marks suspicious areas on a mammogram for the radiologist to review.

Volpara will be integrated into iCADa�s current version 7.2 software platform for SecondLook Digital, and will be available as an upgrade to current customers. The integrated solution will be demonstrated as a work in progress at iCADa�s booth #400 at the Society of Breast Imaginga�s SBI 2011 conference, May 18-21 in San Antonio, TX.

About Mtakina International Limited

Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Mtakina International Ltd is the wholly owned sales and marketing arm of Mtakina Technology Limited of New Zealand. Mtakina International Ltda�s founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK, Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxforda�s most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent^� eBxa" electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].

For iCAD, contact Kevin Burns at 937-431-7967 or via email at [ kburns@icadmed.com ]

For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at [ afields@lhai.com ]

For iCAD media inquiries, contact Wendy Ryan of Schwartz Communications, 781-684-0770, [ wryan@schwartzcomm.com ]

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companya�s ability to defend itself in litigation matters, the Companya�s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Companya�s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCADa�s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Companya�s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at [ http://www.icadmed.com ] and on the SECa�s website at [ http://www.sec.gov ].

N@N

iCAD and Matakina to Integrate Breast Density Assessment with CAD for Mammography